CST-2032 is a brain-permeant, selective adrenoceptor modulator designed to target key receptors in cortical and limbic regions of the brain that are no longer optimally innervated in patients with neurodegenerative disease.
CST-2032 is being developed to treat the debilitating symptoms of neurodegeneration in patients battling Parkinson's, Alzheimer's and related neurodegenerative diseases, and slow or reverse underlying pathology.
The company's initial studies in healthy volunteers and then patients will measure potential for drug impact on core disease symptoms, including dysfunction in cognition, arousal, memory and mood, as well as brain inflammation and metabolic health.
Neurons in the locus coeruleus, located in the brain stem and the sole source of noradrenaline (or norepinephrine) for the higher brain centers, decline very early in neurodegenerative diseases.
By activating specific receptors in the brain, CST-2032 is expected to restore healthy function to multiple cell types, including neurons, microglia, pericytes and astrocytes.
This heterocellular approach is expected to broadly improve cerebral integrity and function, and represents a unique treatment paradigm in the field.
CuraSen's early clinical development work included three clinical trials using established drugs in more than 100 healthy subjects and patients.
The goal was to guide optimization of the company's proprietary compounds, identify meaningful clinical biomarkers and endpoints, and establish exposure and dose levels for proof-of-concept efficacy studies.
The company explored multiple pharmacodynamic measurements for rapid and objective assessment of drug effect on brain function in these trials.
These measures included chemical biomarkers, neuroimaging, neurophysiology and autonomic function assessments of drug-target engagement, as well as more standard tests of arousal, mood and cognitive performance.
The Phase 1 trial will include up to 70 healthy volunteers and patients with a variety of neurodegenerative diseases, including Parkinson's Disease or Mild Cognitive Impairment.
The study will consist of single-ascending and multiple-ascending dose components in healthy volunteers using biomarker assessments, including neuroimaging and autonomic function tests.
A third component will evaluate these measures in patients after receiving CST-2032 treatment. The study is taking place in New Zealand and Belgium.
A Phase 2 study is anticipated to begin in 2021.
CuraSen is focused on the development of new treatments for a variety of neurodegenerative diseases, including Parkinson's Disease, Alzheimer's Disease and other related orphan conditions.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients